---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-157388"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2025-07-10T23:59:59+00:00"
generated_at: "2026-05-18T08:41:49.995453+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Jazz Pharma appoints Renee Gala as President & CEO, effective Aug 11, 2025; Cozadd remains Chair

## Summary
- Renee Gala, previously President & COO, becomes President & CEO effective August 11, 2025, and joins the Board.
- Bruce Cozadd retires as CEO on Aug 11, transitions to advisor through Sep 12, then remains Chairperson.
- Gala's base salary increases to $1.2M (from $900k); target bonus rises to 110% of salary (from 80%).
- Gala receives a one-time promotion equity grant of ~$6.5M (33% RSUs, 67% PSUs) on top of $6M annual grant.
- Severance enhanced: lump sum of 150% base salary (was 100%) and COBRA coverage extended to 18 months.

## SEC filing metadata
- accession: 0001193125-25-157388
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2025-07-10T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000119312525157388/0001193125-25-157388-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000119312525157388/d15137d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-157388
- JSON: https://secwatch.observer/filing/0001193125-25-157388.json
- Plain text: https://secwatch.observer/filing/0001193125-25-157388.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.